Tarbox Family Office’s Accelerate Diagnostics AXDX Stock Holding History

Tarbox Family Office’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-48	Closed	-$1K	–	199
2022 Q1	$1K	Hold	48	–	–	﹤0.01%	907
2021 Q4	$2K	Hold	48	–	–	﹤0.01%	845
2021 Q3	$3K	Hold	48	–	–	﹤0.01%	759
2021 Q2	$4K	Hold	48	–	–	﹤0.01%	687
2021 Q1	$4K	Hold	48	–	–	﹤0.01%	614
2020 Q4	$4K	Hold	48	–	–	﹤0.01%	574
2020 Q3	$5K	Hold	48	–	–	﹤0.01%	471
2020 Q2	$7K	Hold	48	–	–	﹤0.01%	425
2020 Q1	$4K	Hold	48	–	–	﹤0.01%	450
2019 Q4	$8K	Hold	48	–	–	﹤0.01%	408
2019 Q3	$9K	Hold	48	–	–	﹤0.01%	352
2019 Q2	$11K	Hold	48	–	–	﹤0.01%	319
2019 Q1	$10K	Hold	48	–	–	﹤0.01%	305
2018 Q4	$5K	Hold	48	–	–	﹤0.01%	375
2018 Q3	$11K	Hold	48	–	–	﹤0.01%	303
2018 Q2	$11K	Hold	48	–	–	﹤0.01%	292
2018 Q1	$11K	Buy	+48	New	+$12.6K	﹤0.01%	302

Other funds holding AXDX

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Tarbox Family Office's AXDX Position: Q2 2022 in Review

Tarbox Family Office sold out of Accelerate Diagnostics (AXDX) in Q2 2022, closing a stake of 48 shares — an estimated $1K sold.

Tarbox Family Office first reported a position in AXDX in Q1 2018 and held it in 17 quarters. The position peaked at $11K in Q2 2019. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

Tarbox Family Office reported no remaining Accelerate Diagnostics position as of Q2 2022 after selling out during the quarter.
Tarbox Family Office sold 48 Accelerate Diagnostics shares in Q2 2022, an estimated $1K.
Tarbox Family Office first reported a position in Accelerate Diagnostics in Q1 2018 and held it in 17 quarters.
Tarbox Family Office's Accelerate Diagnostics position peaked at $11K in Q2 2019.
74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on Tarbox Family Office's 13F filing for Q2 2022, filed 19 Jul 2022.